78684-63-6

Basic information

• Product Name: R-(-)-Mianserin
• Synonyms: (-)-(R)-Mianserin;(R)-Mianserin;Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (14bR)- (9CI);Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (R)-;R-(-)-Mianserin
• CAS NO: 78684-63-6
• Molecular Formula: C18H20 N2
• Molecular Weight: 264.36
• Mol File: 78684-63-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 411.3°C at 760 mmHg
• Flash Point: 186.1°C
• Appearance: /
• Density: 1.18g/cm³
• Vapor Pressure: 5.65E-07mmHg at 25°C
• Refractive Index: 1.663
• CAS DataBase Reference: R-(-)-Mianserin(CAS DataBase Reference)
• NIST Chemistry Reference: R-(-)-Mianserin(78684-63-6)
• EPA Substance Registry System: R-(-)-Mianserin(78684-63-6)

Safety Data

• Hazardous Substances Data: 78684-63-6(Hazardous Substances Data)

Usage

Uses

(R)-(+)-Mianserin is serotonin receptor antagonist. Antidepressant.

InChI:InChI=1/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3/t18-/m0/s1

Upstream product

• 24219-97-4 mianserin 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 2743-38-6 O,O'-dibenzoyl-L-tartaric acid 
• 22270-22-0 N-(2-chloroethyl)-N-methyl-β-chloro-β-phenylethylamine 
• 448296-34-2 5-methoxy-2-methyl-1,2,3,4,9,13b-hexahydro-2,4a-diaza-tribenzo[a,c,e]cycloheptene 
• 205877-13-0 (2-amino-3-methoxyphenyl)methanol 
• 23175-16-8 β-hydroxy-N-methyl-N-hydroxyethylphenylethylamine 
• 96-09-3 styrene oxide 
• 642442-06-6 (14bR)-2-[(1'S)-1'-phenylethyl]-1,2,10,14b-tetrahydrodibenzo[c,f]pyrazino[1,2-a]azepine-3,4-dione 
• 50-00-0 formaldehyd 
• 642442-08-8 (14bR)-2-[(1'S)-1'-phenylethyl]-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine 

Relevant articles and documents

Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase

A modified macrocyclic glycopeptide-based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide-based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide-based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary behavior with these glycopeptides. A screening procedure was used based on previous work for the enantiomeric separation of 50 chiral compounds including amino acids, pesticides, stimulants, and a variety of pharmaceuticals. Fast and efficient chiral separations resulted by using superficially porous (core-shell) particle supports. Overall, the vancomycin Edman degradation product (EDP) resembled TeicoShell with high enantioselectivity for acidic compounds in the polar ionic mode. The simultaneous enantiomeric separation of 5 racemic profens using liquid chromatography-mass spectrometry with EDP was performed in approximately 3?minutes. Other highlights include simultaneous liquid chromatography separations of rac-amphetamine and rac-methamphetamine with VancoShell, rac-pseudoephedrine and rac-ephedrine with NicoShell, and rac-dichlorprop and rac-haloxyfop with TeicoShell.

Stereoselective synthesis of (R)-(-)-mianserin

(14bR)-2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine, (R)-(-)-mianserin 1a was synthesised in several steps in good enantiomeric purity with the use of (S)-(-)-α-methylbenzylamine 5. The absolute configuration was assigned on the bas

Direct gaschromatographic separation of drug racemates

For inspection of the direct separability of synthetic drug racemates through GC/MS a uniform scheme is proposed and checked with 35 drugs and two cyclodextrin capillary columns. All investigated analytes vaporized without decomposition, 26 of them are separable in the enantiomers, among them 10 with separation to the baseline and 14 with CO-NH-structure.